Venom immunotherapy in patients with mastocytosis and hymenoptera venom anaphylaxis

Immunotherapy

Volumn 3, Issue 5, 2011, Pages 637-651

  González De Olano, David ^a,b   Álvarez Twose, Iván ^b   Vega, Arantza ^b,c   Orfao, Alberto ^b,d   Escribano, Luis ^b  

^a HOSPITAL UNIVERSITARIO DE FUENLABRADA   (Spain)

^b HOSPITAL VIRGEN DE LA SALUD   (Spain)

^c HOSPITAL UNIVERSITARIO DE GUADALAJARA   (Spain)

^d Centro de Investigacion del Cancer   (Spain)

Author keywords

clonal mast cell activation syndrome; hymenoptera venom anaphylaxis; mastocytosis; serum baseline tryptase; venom immunotherapy

Indexed keywords

HYMENOPTERA VENOM; IMMUNOGLOBULIN E; PLACEBO; TRYPTASE;

ANAPHYLAXIS; CELL ACTIVATION; CLINICAL PROTOCOL; CLONAL VARIATION; DISEASE ASSOCIATION; HUMAN; HYMENOPTERA VENOM ANAPHYLAXIS; IMMUNOTHERAPY; MAST CELL; MASTOCYTOSIS; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK FACTOR; TREATMENT DURATION; VENOM IMMUNOTHERAPY; WORLD HEALTH ORGANIZATION;

ANAPHYLAXIS; ANIMALS; ARTHROPOD VENOMS; FEMALE; HUMANS; HYMENOPTERA; IMMUNOTHERAPY; MALE; MAST CELLS; MASTOCYTOSIS; PREVALENCE; TREATMENT OUTCOME; TRYPTASES;

EID: 79955928098     PISSN: 1750743X     EISSN: None     Source Type: Journal    
DOI: 10.2217/imt.11.44     Document Type: Review

References (124)

1. Braun LIB: Notes on desensitization of a patient hypersensitive to bee sting. S. African Med. Rec. 23, 408-409 (1925).
2. Barnard JH: Studies of 400 Hymenoptera sting deaths in the United States. J. Allergy Clin. Immunol. 52(5), 259-264 (1973).
3. Hunt KJ, Valentine MD, Sobotka AK, Benton AW, Amodio FJ, Lichtenstein LM: A controlled trial of immunotherapy in insect hypersensitivity. N. Engl. J. Med. 299(4), 157-161 (1978).
4. Muller U, Thurnheer U, Patrizzi R, Spiess J, Hoigne R: Immunotherapy in bee sting hypersensitivity. Bee venom versus wholebody extract. Allergy 34(6), 369-378 (1979).
5. Bousquet J, Lockey R, Malling HJ: Allergen immunotherapy: therapeutic vaccines for allergic diseases. A WHOposition paper. J. Allergy Clin. Immunol. 102(4 Pt 1), 558-562 (1998).
6. Position paper: Immunotherapy with hymenoptera venoms. (EAACI) The European Academy of Allergology and Clinical Immunology. Allergy 48(Suppl. 14), 36-46 (1993).
7. Bonifazi F, Jutel M, Bilo BM, Birnbaum J, Muller U: Prevention and treatment of hymenoptera venom allergy: guidelines for clinical practice. Allergy 60(12), 1459-1470 (2005).
8. King TP, Spangfort MD: Structure and biology of stinging insect venom allergens. Int. Arch. Allergy Immunol. 123(2), 99-106 (2000).
9. De Graaf DC, Aerts M, Danneels E, Devreese B: Bee, wasp and ant venomics pave the way for a component-resolved diagnosis of sting allergy. J. Proteomics 72(2), 145-154 (2009).
10. Nasser SM, Ying S, Meng Q, Kay AB, Ewan PW: Interleukin-10 levels increase in cutaneous biopsies of patients undergoing wasp venom immunotherapy. Eur. J. Immunol. 31(12), 3704-3713 (2001).
11. Pierkes M, Bellinghausen I, Hultsch T, Metz G, Knop J, Saloga J: Decreased release of histamine and sulfidoleukotrienes by human peripheral blood leukocytes after wasp venom immunotherapy is partially due to induction of IL-10 and IFN-γ production of T cells. J. Allergy Clin. Immunol. 103(2 Pt 1), 326-332 (1999).
12. Sainte-Laudy J, Sabbah A, Drouet M, Lauret MG, Loiry M: Diagnosis of venom allergy by flow cytometry. Correlation with clinical history, skin tests, specific IgE, histamine and leukotriene C4 release. Clin. Exp. Allergy 30(8), 1166-1171 (2000).
13. Brouet JC: Anaphylaxis and systemic mastocytosis. J. Clin. Pathol. 32(8), 854 (1979).
14. Muller UR, Horat W, Wuthrich B, Conroy M, Reisman RE: Anaphylaxis after Hymenoptera stings in three patients with urticaria pigmentosa. J. Allergy Clin. Immunol. 72(6), 685-689 (1983).
15. Fricker M, Helbling A, Schwartz L, Muller U: Hymenoptera sting anaphylaxis and urticaria pigmentosa: clinical findings and results of venom immunotherapy in ten patients. J. Allergy Clin. Immunol. 100(1), 11-15 (1997).
16. Ludolph-Hauser D, Rueff F, Fries C, Schopf P, Przybilla B: Constitutively raised serum concentrations of mast-cell tryptase and severe anaphylactic reactions to Hymenoptera stings. Lancet 357(9253), 361-362 (2001).
17. Biedermann T, Rueff F, Sander CA, Przybilla B: Mastocytosis associated with severe wasp sting anaphylaxis detected by elevated serum mast cell tryptase levels. Br. J. Dermatol. 141(6), 1110-1112 (1999).
18. Oude Elberink JN, De Monchy JG, Kors JW, Van Doormaal JJ, Dubois AE: Fatal anaphylaxis after a yellow jacket sting, despite venom immunotherapy, in two patients with mastocytosis. J. Allergy Clin. Immunol. 99(1 Pt 1), 153-154 (1997).
19. Haeberli G, Bronnimann M, Hunziker T, Muller U: Elevated basal serum tryptase and hymenoptera venom allergy: relation to severity of sting reactions and to safety and efficacy of venom immunotherapy. Clin. Exp. Allergy 33(9), 1216-1220 (2003).
20. Kors JW, Van Doormaal JJ, De Monchy JG: Anaphylactoid shock following hymenoptera sting as a presenting symptom of systemic mastocytosis. J. Intern. Med. 233(3), 255-258 (1993).
21. Dubois AE: Mastocytosis and hymenoptera allergy. Curr. Opin. Allergy Clin. Immunol. 4(4), 291-295 (2004).
22. Florian S, Krauth MT, Simonitsch-Klupp I et al.: Indolent systemic mastocytosis with elevated serum tryptase, absence of skin lesions, and recurrent severe anaphylactoid episodes. Int. Arch. Allergy Immunol. 136(3), 273-280 (2005).
23. Gonzalez De Olano D, De La Hoz Caballer B, Nunez Lopez R et al.: Prevalence of allergy and anaphylactic symptoms in 210 adult and pediatric patients with mastocytosis in Spain: a study of the Spanish Network on Mastocytosis (REMA).Clin. Exp. Allergy 37(10), 1547-1555 (2007).
24. Potier A, Lavigne C, Chappard D et al.: Cutaneous manifestations in Hymenoptera and Diptera anaphylaxis: relationship with basal serum tryptase. Clin. Exp. Allergy 39(5), 717-725 (2009).
25. Bonadonna P, Zanotti R, Caruso B et al.: Allergen specific immunotherapy is safe and effective in patients with systemic mastocytosis and Hymenoptera allergy. J. Allergy Clin. Immunol. 121(1), 256-257 (2008).
26. Dugas-Breit S, Przybilla B, Dugas M et al.: Serum concentration of baseline mast cell tryptase: evidence for a decline during long-term immunotherapy for Hymenoptera venom allergy. Clin. Exp. Allergy 40(4), 643-649 (2010).
27. Guenova E, Volz T, Eichner M et al.: Basal serum tryptase as risk assessment for severe Hymenoptera sting reactions in elderly. Allergy 65(7), 919-923 (2010).
28. Sonneck K, Florian S, Mullauer L et al.: Diagnostic and subdiagnostic accumulation of mast cells in the bone marrow of patients with anaphylaxis: monoclonal mast cell activation syndrome. Int. Arch. Allergy Immunol. 142(2), 158-164 (2007).
29. Akin C, Scott LM, Kocabas CN et al.: Demonstration of an aberrant mast-cell population with clonal markers in a subset of patients with 'idiopathic' anaphylaxis. Blood 110(7), 2331-2333 (2007).
30. Alvarez-Twose I, Gonzalez De Olano D, Sanchez-Munoz L et al.: Clinical, biological, and molecular characteristics of clonal mast cell disorders presenting with systemic mast cell activation symptoms. J. Allergy Clin. Immunol. 125(6), 1269-1278 E1262 (2010).
31. Bonadonna P, Perbellini O, Passalacqua G et al.: Clonal mast cell disorders in patients with systemic reactions to Hymenoptera stings and increased serum tryptase levels. J. Allergy Clin. Immunol. 123(3), 680-686 (2009).
32. Valent P, Akin C, Escribano L et al.: Standards and standardization in mastocytosis: consensus statements on diagnostics, treatment recommendations and response criteria. Eur. J. Clin. Invest. 37(6), 435-453 (2007).
33. Engler RJ, Davis WS: Rush Hymenoptera venom immunotherapy: successful treatment in a patient with systemic mast cell disease. J. Allergy Clin. Immunol. 94(3 Pt 1), 556-559 (1994).
34. Rueff F, Placzek M, Przybilla B: Mastocytosis and hymenoptera venom allergy. Curr. Opin. Allergy Clin. Immunol. 6(4), 284-288 (2006).
35. Gonzalez De Olano D, Alvarez-Twose I, Esteban-Lopez MI et al.: Safety and effectiveness of immunotherapy in patients with indolent systemic mastocytosis presenting with hymenoptera venom anaphylaxis. J. Allergy Clin. Immunol. 121(2), 519-526 (2008).
36. Rueff F, Wenderoth A, Przybilla B: Patients still reacting to a sting challenge while receiving conventional hymenoptera venom immunotherapy are protected by increased venom doses. J. Allergy Clin. Immunol. 108(6), 1027-1032 (2001).
37. Galli SJ, Dvorak AM, Dvorak HF: Basophils and mast cells: morphologic insights into their biology, secretory patterns, and function. Prog. Allergy 34, 1-141 (1984).
38. Fukuoka Y, Xia HZ, Sanchez-Munoz LB, Dellinger AL, Escribano L, Schwartz LB: Generation of anaphylatoxins by human β-tryptase from C3, C4, and C5. J. Immunol. 180(9), 6307-6316 (2008).
39. Nunez-Lopez R, Escribano L, Schernthaner GH et al.: Overexpression of complement receptors and related antigens on the surface of bone marrow mast cells in patients with systemic mastocytosis. Br. J. Haematol. 120(2), 257-265 (2003).
40. Katz HR, Raizman MB, Gartner CS, Scott HC, Benson AC, Austen KF: Secretory granule mediator release and generation of oxidative metabolites of arachidonic acid via Fc-IgG receptor bridging in mouse mast cells. J. Immunol. 148(3), 868-871 (1992).
41. Lobell RB, Arm JP, Raizman MB, Austen KF, Katz HR: Intracellular degradation of Fc g RIII in mouse bone marrow culture-derived progenitor mast cells prevents its surface expression and associated function. J. Biol. Chem. 268(2), 1207-1212 (1993).
42. Lobell RB, Austen KF, Katz HR: Fc g R-mediated endocytosis and expression of cell surface Fc g RIIb1 and Fc g RIIb2 by mouse bone marrow culture-derived progenitor mst cells. J. Immunol. 152(2), 811-818 (1994).
43. Woolhiser MR, Brockow K, Metcalfe DD: Activation of human mast cells by aggregated IgG through FcγRI: additive effects of C3a. Clin. Immunol. 110(2), 172-180 (2004).
44. Malaviya R, Gao Z, Thankavel K, Van Der Merwe PA, Abraham SN: The mast cell tumor necrosis factor a response to FimH-expressing Escherichia coli is mediated by the glycosylphosphatidylinositol-anchored molecule CD48. Proc. Natl Acad. Sci. USA 96(14), 8110-8115 (1999).
45. Gommerman JL, Oh DY, Zhou X et al.: A role for CD21/CD35 and CD19 in responses to acute septic peritonitis: a potential mechanism for mast cell activation. J. Immunol. 165(12), 6915-6921 (2000).
46. Supajatura V, Ushio H, Nakao A, Okumura K, Ra C, Ogawa H: Protective roles of mast cells against enterobacterial infection are mediated by Toll-like receptor 4. J. Immunol. 167(4), 2250-2256 (2001).
47. Varadaradjalou S, Feger F, Thieblemont N et al.: Toll-like receptor 2 (TLR2) and TLR4 differentially activate human mast cells. Eur. J. Immunol. 33(4), 899-906 (2003).
48. Boyce JA: Mast cells: beyond IgE. J. Allergy Clin. Immunol. 111(1), 24-32; quiz 33 (2003).
49. Escribano L, Orfao A, Diaz-Agustin B et al.: Indolent systemic mast cell disease in adults: immunophenotypic characterization of bone marrow mast cells and its diagnostic implications. Blood 91(8), 2731-2736 (1998).
50. Valent P, Horny HP, Escribano L et al.: Diagnostic criteria and classification of mastocytosis: a consensus proposal. Leuk. Res. 25(7), 603-625 (2001).
51. Horny HP, Valent P, Metcalfe DD et al.: Mastocytosis. World Health Organization (WHO) classification of tumours. In:Pathology & Genetics. Tumours of Haematopoietic and Lymphoid Tissues. Jaffe ES, Harris NL, Stein H, Vardiman JW (Eds).IARC, Lyon, France 54-63 (2008).
52. Escribano L, Orfao A, Diaz Agustin B et al.: Human bone marrow mast cells from indolent systemic mast cell disease constitutively express increased amounts of the CD63 protein on their surface. Cytometry 34(5), 223-228 (1998).
53. Diaz-Agustin B, Escribano L, Bravo P et al.: The CD69 early activation molecule is overexpressed in human bone marrow mast cells from adults with indolent systemic mast cell disease. Br. J. Haematol. 106(2), 400-405 (1999).
54. Hauswirth AW, Escribano L, Prados A et al.: CD203c is overexpressed on neoplastic mast cells in systemic mastocytosis and is upregulated upon IgE receptor cross-linking. Int. J. Immunopathol. Pharmacol. 21(4), 797-806 (2008).
55. Escribano L, Garcia Montero AC, Nunez R, Orfao A: Flow cytometric analysis of normal and neoplastic mast cells: role in diagnosis and follow-up of mast cell disease. Immunol. Allergy Clin. North Am. 26(3), 535-547 (2006).
56. Escribano L, Diaz-Agustin B, Nunez R, Prados A, Rodriguez R, Orfao A: Abnormal expression of CD antigens in mastocytosis. Int. Arch. Allergy Immunol. 127(2), 127-132 (2002).
57. Teodosio C, Garcia-Montero AC, Jara-Acevedo M et al.: Mast cells from different molecular and prognostic subtypes of systemic mastocytosis display distinct immunophenotypes. J. Allergy Clin. Immunol. 125(3), 719-726, 726.E1-726.E4 (2010).
58. Sperr WR, Escribano L, Jordan JH et al.: Morphologic properties of neoplastic mast cells: delineation of stages of maturation and implication for cytological grading of mastocytosis. Leuk. Res. 25(7), 529-536 (2001).
59. Horny HP, Sillaber C, Menke D et al.: Diagnostic value of immunostaining for tryptase in patients with mastocytosis. Am. J. Surg. Pathol. 22(9), 1132-1140 (1998).
60. Horny HP, Valent P: Diagnosis of mastocytosis: general histopathological aspects, morphological criteria, and immunohistochemical findings. Leuk. Res. 25(7), 543-551 (2001).
61. Escribano L, Diaz-Agustin B, Lopez A et al.: Immunophenotypic analysis of mast cells in mastocytosis: when and how to do it. Proposals of the Spanish Network on Mastocytosis (REMA).Cytometry B Clin. Cytom. 58(1), 1-8 (2004).
62. Sotlar K, Escribano L, Landt Oet al.: One-step detection of c-kit point mutations using peptide nucleic acid-mediated polymerase chain reaction clamping and hybridization probes. Am. J. Pathol. 162(3), 737-746 (2003).
63. Garcia-Montero AC, Jara-Acevedo M, Teodosio C et al.: KIT mutation in mast cells and other bone marrow hematopoietic cell lineages in systemic mast cell disorders: a prospective study of the Spanish Network on Mastocytosis (REMA) in a series of 113 patients. Blood 108(7), 2366-2372 (2006).
64. Akin C, Valent P, Metcalfe DD: Mast cell activation syndrome: Proposed diagnostic criteria. J. Allergy Clin. Immunol. 126(6), 1099-1104 E1094 (2010).
65. Metcalfe DD: Clinical advances in mastocytosis: an interdisciplinary roundtable discussion. J. Invest. Dermatol. 96(Suppl.), S1-S65 (1991).
66. Álvarez-Twose I, Gonzalez De Olano D, Sánchez-Muñoz L et al.: Clinical, biological and molecular characterisitics of mast cell activation disorders: a prospective study in 62 patients by the Spanish Network on Mastocytosis (REMA).J. Allergy Clin. Immunol. 123, S141 (2009).
67. Orfao A, Escribano L, Villarrubia J et al.: Flow cytometric analysis of mast cells from normal and pathological human bone marrow samples: identification and enumeration. Am. J. Pathol. 149(5), 1493-1499 (1996).
68. Bohlke K, Davis RL, Destefano F, Marcy SM, Braun MM, Thompson RS: Epidemiology of anaphylaxis among children and adolescents enrolled in a health maintenance organization. J. Allergy Clin. Immunol. 113(3), 536-542 (2004).
69. Mullins RJ: Anaphylaxis: risk factors for recurrence. Clin. Exp. Allergy 33(8), 1033-1040 (2003).
70. Peng MM, Jick H: A population-based study of the incidence, caus, and severity of anaphylaxis in the United Kingdom. Arch. Intern. Med. 164(3), 317-319 (2004).
71. Moneret-Vautrin DA, Morisset M, Flabbee J, Beaudouin E, Kanny G: Epidemiology of life-threatening and lethal anaphylaxis: a review. Allergy 60(4), 443-451 (2005).
72. Brockow K, Jofer C, Behrendt H, Ring J: Anaphylaxis in patients with mastocytosis: a study on history, clinical features and risk factors in 120 patients. Allergy 63(2), 226-232 (2008).
73. Metcalfe DD, Schwartz LB: Assessing anaphylactic risk? Consider mast cell clonality. J. Allergy Clin. Immunol. 123(3), 687-688 (2009).
74. Muller UR, Haeberli G: The problem of anaphylaxis and mastocytosis. Curr. Allergy Asthma Rep. 9(1), 64-70 (2009).
75. Bonadonna P, Zanotti R, Pagani M et al.: How much specific is the association between hymenoptera venom allergy and mastocytosis? Allergy 64(9), 1379-1382 (2009).
76. Simons FE, Frew AJ, Ansotegui IJ et al.: Practical allergy (PRACTALL) report: risk assessment in anaphylaxis. Allergy 63(1), 35-37 (2008).
77. Schwartz LB, Yunginger JW, Miller J, Bokhari R, Dull D: Time course of appearance and disappearance of human mast cell tryptase in the circulation after anaphylaxis. J. Clin. Invest. 83(5), 1551-1555 (1989).
78. Orfao A, Garcia-Montero AC, Sanchez L, Escribano L: Recent advances in the understanding of mastocytosis: the role of KIT mutations. Br. J. Haematol. 138(1), 12-30 (2007).
79. Schwartz LB, Min HK, Ren S et al.: Tryptase precursors are preferentially and spontaneously released, whereas mature tryptase is retained by HMC-1 cells, Mono-Mac-6 cells, and human skin-derived mast cells. J. Immunol. 170(11), 5667-5673 (2003).
80. Schwartz LB, Metcalfe DD, Miller JS, Earl H, Sullivan T: Tryptase levels as an indicator of mast-cell activation in systemic anaphylaxis and mastocytosis. N. Engl. J. Med. 316(26), 1622-1626 (1987).
81. Rueff F, Przybilla B, Bilo MB et al.: Predictors of side effects during the buildup phase of venom immunotherapy for Hymenoptera venom allergy: the importance of baseline serum tryptase. J. Allergy Clin. Immunol. 126(1), 105-111 E105 (2010).
82. Bonadonna P, Zanotti R, Muller U: Mastocytosis and insect venom allergy. Curr. Opin. Allergy Clin. Immunol. 10(4), 347-353 (2010).
83. Simons FE, Frew AJ, Ansotegui IJ et al.: Risk assessment in anaphylaxis: current and future approaches. J. Allergy Clin. Immunol. 120(Suppl. 1), S2-S24 (2007).
84. Bilo BM, Rueff F, Mosbech H, Bonifazi F, Oude-Elberink JN: Diagnosis of Hymenoptera venom allergy. Allergy 60(11), 1339-1349 (2005).
85. Position paper: Allergen standardization and skin tests. The European Academy of Allergology and Clinical Immunology. Allergy 48(Suppl. 14), 48-82 (1993).
86. Portnoy JM, Moffitt JE, Golden DB et al.: Stinging insect hypersensitivity: a practice parameter. The Joint Force on Practice Parameters, the American Academy of Allergy, Asthma and Immunology, the American College of Allergy, Asthma and Immunology, and the Joint Council of Allergy, Asthma and Immunology. J. Allergy Clin. Immunol. 103(5 Pt 1), 963-980 (1999).
87. Muller U, Helbling A, Hunziker T et al.: Mastocytosis and atopy: a study of 33 patients with urticaria pigmetosa. Allergy 45(8), 597-603 (1990).
88. Bilo BM: Diagnosis of insect venom allergy: skin tests and serum specific IgE. In:Hymenoptera Venom Allergy. The European Academy Allergy Monographs. Ollert M (Ed.).EAACI, Ancona, Italy 21-25 (2009).
89. Goldberg A, Confino-Cohen R: Timing of venom skin tests and IgE determinations after insect sting anaphylaxis. J. Allergy Clin. Immunol. 100(2), 182-184 (1997).
90. Rieger-Ziegler V, Rieger E, Kranke B, Aberer W: Hymenoptera venom allergy: time course of specific IgE concentrations during the first weeks after a sting. Int. Arch. Allergy Immunol. 120(2), 166-168 (1999).
91. Golden DB, Kagey-Sobotka A, Norman PS, Hamilton RG, Lichtenstein LM: Insect sting allergy with negative venom skin test responses. J. Allergy Clin. Immunol. 107(5), 897-901 (2001).
92. Kranke B, Sturm G, Aberer W: Negative venom skin test results and mastocytosis. J. Allergy Clin. Immunol. 113(1), 180-181 (2004).
93. Golden DB, Tracy JM, Freeman TM, Hoffman DR: Negative venom skin test results in patients with histories of systemic reaction to a sting. J. Allergy Clin. Immunol. 112(3), 495-498 (2003).
94. Kleine-Tebbe J, Erdmann S, Knol EF, Macglashan DW Jr, Poulsen LK, Gibbs BF: Diagnostic tests based on human basophils: potentials, pitfalls and perspectives. Int. Arch. Allergy Immunol. 141(1), 79-90 (2006).
95. De Weck AL, Sanz ML, Gamboa PM et al.: Diagnostic tests based on human basophils: more potentials and perspectives than pitfalls. Int. Arch. Allergy Immunol. 146(3), 177-189 (2008).
96. Gonzalez-De-Olano D, Alvarez-Twose I, Morgado JM et al.: Evaluation of basophil activation in mastocytosis with hymenoptera venom anaphylaxis. Cytometry B Clin. Cytom. (2010).
97. Eberlein-Konig B, Rakoski J, Behrendt H, Ring J: Use of CD63 expression as marker of in vitro basophil activation in identifying the culprit in insect venom allergy. J. Investig. Allergol. Clin. Immunol. 14(1), 10-16 (2004).
98. Rueff F, Dugas-Breit S, Bauer C: Diagnosis and treatment of hymenoptera venom allergy in mastocytosis. Allergo J. 14, 514-515 (2005).
99. Bernstein IL, Li JT, Bernstein DI et al.: Allergy diagnostic testing: an updated practice parameter. Ann. Allergy Asthma Immunol. 100(3 Suppl. 3), S1-148 (2008).
100. Golden DB: Insect sting anaphylaxis. Immunol. Allergy Clin. North Am. 27(2), 261-272, VII (2007).
101. Bilo MB, Brianzoni F, Cinti B, Napoli G, Bonifazi F: The dilemma of the negative skin test reactors with a history of venom anaphylaxis: will this always be the case? Eur. Ann. Allergy Clin. Immunol. 37(9), 341-342 (2005).
102. Akdis CA, Akdis M: Mechanisms of allergen-specific immunotherapy. J. Allergy Clin. Immunol. 121), 18-27 (2011).
103. Golden DB: Insect allergy. In:Middleton's Allergy. Principles & Practice . Adkinson NF, Brochner BS, Busse WW, Holgate ST, Lemanske RF, Simons FE (Eds).Mosby, St Louis, MO, USA 1005-1017 (2009).
104. Golden DB: Insect sting allergy and venom immunotherapy: a model and a mystery. J. Allergy Clin. Immunol. 115(3), 439-447; quiz 448 (2005).
105. Wagner N, Fritze D, Przybilla B, Hagedorn M, Rueff F: Fatal anaphylactic sting reaction in a patient with mastocytosis. Int. Arch. Allergy Immunol. 146(2), 162-163 (2008).
106. Reimers A, Muller UR: Fatal outcome of vespula sting in a patient with mastocytosis after specific immunotherapy with honey bee venom. Allergy Clin. Immunol. Int. J. WAO Org. 17, 68-70 (2005).
107. Golden DB, Kelly D, Hamilton RG, Craig TJ: Venom immunotherapy reduces large local reactions to insect stings. J. Allergy Clin. Immunol. 123(6), 1371-1375 (2009).
108. Goldberg A, Confino-Cohen R: Maintenance venom immunotherapy administered at 3-month intervals is both safe and efficacious. J. Allergy Clin. Immunol. 107(5), 902-906 (2001).
109. Niedoszytko M, De Monchy J, Van Doormaal JJ, Jassem E, Oude Elberink JN: Mastocytosis and insect venom allergy: diagnosis, safety and efficacy of venom immunotherapy. Allergy 64(9), 1237-1245 (2009).
110. Reimers A, Hari Y, Muller U: Reduction of side-effects from ultrarush immunotherapy with honeybee venom by pretreatment with fexofenadine: a double-blind, placebo-controlled trial. Allergy 55(5), 484-488 (2000).
111. Brockow K, Kiehn M, Riethmuller C, Vieluf D, Berger J, Ring J: Efficacy of antihistamine pretreatment in the prevention of adverse reactions to Hymenoptera immunotherapy: a prospective, randomized, placebo-controlled trial. J. Allergy Clin. Immunol. 100(4), 458-463 (1997).
112. Müller UR, Hari Y, Berchtold E: Premedication with antihistamines may enhance efficacy of specific-allergen immunotherapy. J. Allergy Clin. Immunol. 107(1), 81-86 (2001).
113. Müller UR, Jutel M, Reimers A et al.: Clinical and immunologic effects of H1 antihistamine preventive medication during honeybee venom immunotherapy. J. Allergy Clin. Immunol. 122(5), 1001-1007 E4 (2008).
114. Gorska L, Chelminska M, Kuziemski K et al.: Analysis of safety, risk factors and pretreatment methods during rush hymenoptera venom immunotherapy. Int. Arch. Allergy Immunol. 147(3), 241-245 (2008).
115. Wöhrl S, Gamper S, Hemmer W, Heinze G, Stingl G, Kinaciyan T: Premedication with montelukast reduces local reactions of allergen immunotherapy. Int. Arch. Allergy Immunol. 144(2), 137-142 (2007).
116. Oren E, Chegini S, Hamilos DL: Ultrarush venom desensitization after systemic reactions during conventional venom immunotherapy. Ann. Allergy Asthma Immunol. 97(5), 606-610 (2006).
117. Kontou-Fili K: High omalizumab dose controls recurrent reactions to venom immunotherapy in indolent systemic mastocytosis. Allergy 63(3), 376-378 (2008).
118. Wedi B, Wieczorek D, Roap V, Kapp A: Anti-IgE treatment overcomes intolerability of honey bee venom ultra-rush immunotherapy in indolent systemic mastocytosis. J. World Allergy Org. (Suppl. 2), 182-183 (2007).
119. Schulze J, Rose M, Zielen S: Beekeepers anaphylaxis: successful immunotherapy covered by omalizumab. Allergy 62(8), 963-964 (2007).
120. Carter MC, Robyn JA, Bressler PB, Walker JC, Shapiro GG, Metcalfe DD: Omalizumab for the treatment of unprovoked anaphylaxis in patients with systemic mastocytosis. J. Allergy Clin. Immunol. 119(6), 1550-1551 (2007).
121. Galera C, Soohun N, Zankar N, Caimmi S, Gallen C, Demoly P: Severe anaphylaxis to bee venom immunotherapy: efficacy of pretreatment and concurrent treatment with omalizumab. J. Investig. Allergol. Clin. Immunol. 19(3), 225-229 (2009).
122. Lockey RF, Turkeltaub PC, Olive ES, Hubbard JM, Baird-Warren IA, Bukantz SC: The Hymenoptera venom study. III: safety of venom immunotherapy. J. Allergy Clin. Immunol. 86(5), 775-780 (1990).
123. Moffitt JE, Golden DB, Reisman RE et al.: Stinging insect hypersensitivity: a practice parameter update. J. Allergy Clin. Immunol. 114(4), 869-886 (2004).
124. Golden DB: Long-term outcome after venom immunotherapy. Curr. Opin. Allergy Clin. Immunol. 10(4), 337-341 (2010).